KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2025)

Adaptive Biotechnologies' Cash & Equivalents history spans 8 years, with the latest figure at $70.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 47.11% year-over-year to $70.5 million; the TTM value through Dec 2025 reached $70.5 million, up 47.11%, while the annual FY2025 figure was $70.5 million, 47.11% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $70.5 million at Adaptive Biotechnologies, up from $55.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $217.6 million in Q3 2022 and bottomed at $38.1 million in Q3 2024.
  • The 5-year median for Cash & Equivalents is $82.6 million (2022), against an average of $95.6 million.
  • The largest annual shift saw Cash & Equivalents crashed 75.38% in 2021 before it skyrocketed 77.74% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $139.1 million in 2021, then tumbled by 35.26% to $90.0 million in 2022, then fell by 27.73% to $65.1 million in 2023, then dropped by 26.35% to $47.9 million in 2024, then surged by 47.11% to $70.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Cash & Equivalents are $70.5 million (Q4 2025), $55.0 million (Q3 2025), and $43.2 million (Q2 2025).